Great and inspiring #microbiome meeting with celebrities of the field. Thanks to Andre, Vanessa, Philip and Anita for the organisation and invitation. bmsd.science

Nice talk by Jonel Trebicka presenting the results of @TransHep_GUF from the last two years on portal hypertension and liver fibrosis.

Doctors and scientists need to speak the same language, say two new PhD4MD fellows IDIBAPS LIVERHOPE.
#EndHep #HealthForAll 🇪🇺 Marko EU One Health Vytenis Andriukaitis WHO/Europe ECDC HIV AIDS ECDC EU drugs agency Carlos Moedas
irbbarcelona.org/en/news/in-viv…

Prof. Elsa Sola presented Design and endpoints of clinical trials in decompensated cirrhosis.
LIVERHOPE
#EndHep #HealthForAll 🇪🇺 Marko EU One Health Vytenis Andriukaitis WHO/Europe ECDC HIV AIDS ECDC EU drugs agency Carlos Moedas

Marta Carol from IDIBAPS, Spain presented improvements we plan in nursing care with patients with cirrhosis.Prof.
LIVERHOPE
#EndHep #HealthForAll 🇪🇺 Marko EU One Health WHO/Europe ECDC HIV AIDS ECDC EU drugs agency

LIVERHOPE project will intruduce the first document about nurses care of cirrotic patients in the world, said Prof. Pere Gines
LIVERHOPE
#EndHep #HealthForAll 🇪🇺 Marko EU One Health Vytenis Andriukaitis WHO/Europe ECDC HIV AIDS ECDC EU drugs agency Carlos Moedas Antons Mozalevskis

Looking forward to start the second annual MEETING LIVERHOPE in Barcelona.
Prof. Pere Gines prepares the final points before the start of the meeting #EndHep in 🇪🇺 #HealthForAll Marko ASSCAT

Prof. Pere Gines:
LIVERHOPE project will have and already has several positive points that needs to be addressed. Stigma, lack of knowledge...
#EndHep #HealthForAll 🇪🇺 Marko EU One Health Vytenis Andriukaitis WHO/Europe ECDC HIV AIDS ECDC EU drugs agency Carlos Moedas Antons Mozalevskis

Prof. Pere Gines opens the LIVERHOPE meeting in Barcelona.
Excellent start new hope with new therapy for patients with decompensated #cirrosis #EndHep #HealthForAll in 🇪🇺 Marko @ASSCATINFORMA EU One Health Vytenis Andriukaitis WHO/Europe Carlos Moedas ECDC HIV AIDS ECDC

On 26th April, Aleksander Krag received
the Order of Odd Fellow's Research prize for an outstanding contribution to
Danish Research - there was a ceremony with many nobelties including
representatives from the royal family (Her Royal Highness Princess Benedikte). Congrats!

This is too good😝😝 Arthur !

A case of the reversed curves? Higher portal concentration of C4M, collagen 4 (basement membrane) degradation product, increase survival in men but reduce survival in women. Now in press Liver International From GALAXY @TransHep_GUF Nordic Bioscience

Leversyge patienter skal findes i tide! Det kræver bedre samarbejde mellem almen praktiserende læge, sygehus og #leverforskning og så skal vi benytte alle de nye muligheder som #AI byder på. sdu.dk/da/nyheder/for… @SUND_SDU @SyddanskUniv

Our biggest fans this week: MICROB-PREDICT, Jonel Trebicka, @TransHep_GUF. Thank you! via sumall.com/thankyou?utm_s…

Mechanosensor of angiocrine signaling in the liver discovered. Fundamental insights into vascular control mechanisms of organ function. Great work Ecki!

#Sarcopenia is a predictor of #ACLF and mortality in patients with #cirrhosis after TIPS. Read more about it in our recent collaborative publication published in #ClinicalAndTranslationalGastroenterology .
insights.ovid.com/crossref?an=01…
#openaccess Rheinische Friedrich-Wilhelms-Universität Bonn Goethe-Universität Sapienza Università di Roma

Interview for Romanian health TV. Speaking about next steps in hepatitis elimination and taking the stigma of cured patients.Marko

ELPA is activly involved in VHPB Advisory and a multitopic Technical meetings 24-26 of April in Vilnius, Lithuania

The first meeting dedicated to validation of biomarkers and #biosensor development (WP5) was held at ICN2/Barcelona on 26/03. The aim was to initiate
the collaboration of ICN2 and CEA regarding the development of point of care
tests. Catalan Institute of Nanoscience & Nanotechnology Arben Merkoçi #cirrhosis #microbiome

The EU-funded MICROB-PREDICT is launched! Microbiome experts like EMBL's @Borklab join forces with technology leaders, clinical specialists and patient organisations to understand how the human microbiome contributes to the development of liver disease: bit.ly/2sVnHOV